Copeptin as a marker of outcome after cardiac arrest: A sub-study of the TTM trial

Joachim Düring*, Martin Annborn, Tobias Cronberg, Josef Dankiewicz, Yvan Devaux, Christian Hassager, Janneke Horn, Jesper Kjaergaard, Michael Kuiper, Homa Rafi Nikoukhah, Pascal Stammet, Johan Undén, Michael Jaeger Wanscher, Matt Wise, Hans Friberg, Niklas Nielsen

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

8 Citations (Scopus)


Background: Arginine vasopressin has complex actions in critically ill patients, involving vasoregulatory status, plasma volume, and cortisol levels. Copeptin, a surrogate marker for arginine vasopressin, has shown promising prognostic features in small observational studies and is used clinically for early rule out of acute coronary syndrome. The objective of this study was to explore the association between early measurements of copeptin, circulatory status, and short-term survival after out-of-hospital cardiac arrest. Methods: Serial blood samples were collected at 24, 48, and 72 h as part of the target temperature management at 33 °C versus 36 °C after cardiac arrest trial, an international multicenter randomized trial where unconscious survivors after out-of-hospital cardiac arrest were allocated to an intervention of 33 or 36 °C for 24 h. Primary outcome was 30-day survival with secondary endpoints circulatory cause of death and cardiovascular deterioration composite; in addition, we examined the correlation with extended the cardiovascular sequential organ failure assessment (eCvSOFA) score. Results: Six hundred ninety patients were included in the analyses, of whom 203 (30.3%) developed cardiovascular deterioration within 24 h, and 273 (39.6%) died within 30 days. Copeptin measured at 24 h was found to be independently associated with 30-day survival, hazard ratio 1.17 [1.06-1.28], p = 0.001; circulatory cause of death, odds ratio 1.03 [1.01-1.04], p = 0.001; and cardiovascular deterioration composite, odds ratio of 1.05 [1.02-1.08], p < 0.001. Copeptin at 24 h was correlated with eCvSOFA score with rho 0.19 [0.12-0.27], p < 0.001. Conclusion: Copeptin is an independent marker of severity of the post cardiac arrest syndrome, partially related to circulatory failure. Trial registration: Clinical Trials, NCT01020916. Registered November 26, 2009.

Original languageEnglish
Article number185
JournalCritical Care
Issue number1
Publication statusPublished - 28 Apr 2020


  • AVP protein human
  • Arginine vasopressin
  • Biomarkers
  • Copeptin
  • Critical illness
  • Humans
  • Out-of hospital cardiac arrest
  • Prognosis
  • Survivors


Dive into the research topics of 'Copeptin as a marker of outcome after cardiac arrest: A sub-study of the TTM trial'. Together they form a unique fingerprint.

Cite this